| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01268059 Details | 2020-12-23 Interventional | 1/2 | 99 | Carboplatin Paclitaxel Carcinoma, Non-… Lung Neoplasms Non-small Cell … | In conjunction with the overall risk-benefit assessment, study was terminated prematurely due
to safety concerns. In conjunction with the overall risk-benefit assessment, study was terminated prematurely due to safety concerns. Change in tumor size outcome measure was not analyzed as per changed planned analysis due to premature termination of the study. | |||
| NCT03096340 Details | 2020-12-22 Interventional | 1 | 10 | 10-hydroxycampt… Irinotecan Neoplasms Cancer Recurrent Solid… Refractory Soli… Tumors | Terminated by sponsor. - | |||
| NCT00626197 Details | 2020-12-22 Interventional | 3 | 381 | Azathioprine Cyclophosphamid… Mycophenolic Ac… Ocrelizumab Lupus Erythemat… Lupus Nephritis Nephritis Systemic Lupus … | Study was terminated due to an imbalance of serious and opportunistic infections in the
ocrelizumab treated patients versus the placebo arm. The study was terminated early due to an imbalance in serious infections in ocrelizumab-treated participants versus placebo-treated participants. Only 139 of the 381 participants randomized completed the 48 week treatment period. | |||
| NCT00430716 2006-006748-76 Details | 2020-12-22 Interventional | 4 | 130 | Citric Acid Sildenafil Citr… Sodium Citrate Familial Primar… Hypertension Pulmonary Arter… | This study was terminated at the recommendation of an independent Data Monitoring Committee.
The decision was not based on any safety concerns. The trial was not designed to demonstrate the equivalence of doses and due to premature study termination, the resulting sample size was not adequately powered to show superiority. | |||
| NCT04675086 Details | 2020-12-21 Interventional | 3 | 0 | Alpha 1-Antitry… Antiviral Agent… Protease Inhibi… Remdesivir COVID-19 Pneumonia Pneumonia, Vira… Covid19 | Administrative Decision - | |||
| NCT04511975 Details | 2020-12-21 Interventional | 1 | - | Azacitidine MDS | pause for further assessment and study adjustment - | |||
| NCT04338906 Details | 2020-12-21 Interventional | 4 | 0 | Camostat Hydroxychloroqu… COVID | lack of public funding; planned control arm with Hydroxychloroquine treatment showed out as not
being standard of care anymore as time evolved. - | |||
| NCT02703571 2015-005019-34 Details | 2020-12-21 Interventional | 1 | 95 | Trametinib Colorectal Neop… Pancreatic Neop… Colorectal Canc… Pancreatic Canc… Solid Tumors fo… | Company decision - | |||
| NCT03363776 2017-002199-24 Details | 2020-12-19 Interventional | 1/2 | 10 | Nivolumab Cancer | Business objectives have changed - | |||
| NCT00493766 Details | 2020-12-19 Interventional | 1 | 16 | Panobinostat Prostatic Neopl… Hormone Refract… | Because of a strategic decision by Novartis - | |||
| NCT04671420 Details | 2020-12-17 Interventional | 3 | 0 | Rituximab Lymphoma Lymphoma, Folli… CD20-positive F… | sponsor strategy decision - | |||
| NCT03739606 Details | 2020-12-17 Interventional | 2 | 0 | Antibodies Antibodies, Bis… Antibodies, Mon… Immunoglobulins Hematologic Neo… Hodgkin Disease Leukemia Leukemia, Biphe… Leukemia, Hairy… Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Lymphoma Mastocytosis Mastocytosis, S… Neoplasms Precursor Cell … Recurrence Acute Biphenoty… Acute Leukemia Chronic Myeloge… Hairy Cell Leuk… Interleukin-3 R… Recurrent Acute… Recurrent Blast… Recurrent Chron… Recurrent Hemat… Recurrent Hodgk… Refractory Acut… Refractory Blas… Refractory Hema… Refractory Hodg… Systemic Mastoc… | RSS recommendation - | |||
| NCT03170115 Details | 2020-12-17 Interventional | 2 | 25 | Aspirin Neoplasms Rectal Neoplasm… Chemoradiation Locally Advance… Rectal Cancer, … | Aspirin added to chemoradiotherapy was safe but did not improve response to total neoadjuvant
treatment. The study was closed due absence of benefit. - | |||
| NCT02951156 2016-002904-15 Details | 2020-12-17 Interventional | 3 | 29 | Avelumab Azacitidine Bendamustine Hy… Gemcitabine Oxaliplatin Rituximab Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Diffuse Large B… | Study was terminated due to closure of study arms following futility analysis and difficulty in
enrolling participants due to evolving treatment landscape Data for Phase 3 outcome measures were not collected as study was terminated early and phase 3 was not conducted. | |||
| NCT01856257 Details | 2020-12-17 Interventional | 2 | [1 Refs] | 71 | Abatacept Antilymphocyte … Basiliximab Methylprednisol… Mycophenolic Ac… Tacrolimus Thymoglobulin Kidney Transpla… Primary Renal A… | Safety: Stopping rule not met. - | ||
| NCT01373086 Details | 2020-12-17 Interventional | 2 | 19 | Eplerenone Essential Hyper… Hypertension | - - | |||
| NCT00633997 Details | 2020-12-17 Interventional | 1/2 | 22 | Vildagliptin Diabetes Mellit… Diabetes Mellit… | After analysis of the existing data, it was determined that additional skin biopsy samples
would not be required to determine study outcome. - | |||
| NCT00615784 Details | 2020-12-17 Interventional | 2 | 24 | Bexarotene Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | Study terminated. Eisai's Targretin acquired by another pharmaceutical company. - | |||
| NCT00555789 Details | 2020-12-17 Interventional | 2 | 137 | Tacrolimus Kidney Transpla… | - - | |||
| NCT04366232 2020-001963-10 Details | 2020-12-16 Interventional | 2 | [3 Refs] | 2 | Interleukin 1 R… COVID-19 Inflammation Covid-19 | investigator decision - |